A Phase I, Single Ascending Dose Study of Cimaglermin Alfa (Neuregulin 1β3) in Patients With Systolic Dysfunction and Heart Failure

A first-in-human, phase 1, double blind, placebo-controlled, single ascending dose study examined the safety, tolerability, and exploratory efficacy of intravenous infusion of a recombinant growth factor, cimaglermin alfa, in patients with heart failure and left ventricular systolic dysfunction (LVS...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:JACC Basic Transl Sci
Asıl Yazarlar: Lenihan, Daniel J., Anderson, Sarah A., Lenneman, Carrie Geisberg, Brittain, Evan, Muldowney, James A.S., Mendes, Lisa, Zhao, Ping Z., Iaci, Jennifer, Frohwein, Stephen, Zolty, Ronald, Eisen, Andrew, Sawyer, Douglas B., Caggiano, Anthony O.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Elsevier 2016
Konular:
CLINICAL RESEARCH
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6113538/
https://ncbi.nlm.nih.gov/pubmed/30167542
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jacbts.2016.09.005
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller